文献速递糖尿病性腺与生殖内分泌

睾酮联合SGLT2抑制剂治疗期间红细胞增多症风险:两例临床病例警示

Risk of Erythrocytosis During Concomitant Testosterone and SGLT2-Inhibitor Treatment: A Warning From Two Clinical Cases.
PubMed 文献 · J Clin Endocrinol Metab · 2019-01-01

本文报告两例性腺功能减退合并2型糖尿病患者在接受睾酮替代治疗(TRT)与SGLT2抑制剂(SGLT2i)联合治疗期间出现红细胞增多症的病例。作者指出,性腺功能减退与2型糖尿病常并存,临床医生联合处方TRT与SGLT2i时应密切监测红细胞增多症的发生风险。

要点

  • 所有睾酮制剂均可能升高血红蛋白和红细胞压积,短效注射剂型尤为明显。
  • 性腺功能减退与2型糖尿病常并存,TRT与SGLT2i联用情况日益常见。
  • 联合处方TRT与SGLT2i时应密切监测红细胞增多症风险。

核心结论

  • 性腺功能减退合并2型糖尿病患者在接受睾酮替代治疗与SGLT2抑制剂联合治疗期间可能出现红细胞增多症。
  • 临床医生联合处方TRT与SGLT2i时应仔细监测红细胞增多症的发生风险。

研究设计与样本

  • 本文为两例临床病例报告,患者为性腺功能减退合并2型糖尿病、接受睾酮治疗与SGLT2i治疗者。

主要发现

  • 报告了两例在睾酮治疗与SGLT2i治疗期间发生红细胞增多症的病例。
  • 所有睾酮制剂均可能引起血红蛋白和红细胞压积升高,尤其是短效注射剂型。
  • SGLT2i通过抑制肾脏葡萄糖重吸收、增加尿糖排泄来降低2型糖尿病患者的血糖。

临床怎么用

  • 对性腺功能减退合并2型糖尿病且联合使用TRT与SGLT2i的患者,应密切监测红细胞增多症风险。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Erythrocytosis is one of the most common side effects occurring during testosterone replacement therapy (TRT) in male hypogonadism. It is well known that all testosterone formulations may cause Hb and hematocrit increase, especially with short-acting injectable formulations. Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are a new class of glucose-lowering agents that reduce hyperglycemia in patients with type 2 diabetes mellitus (T2DM) by inhibition of renal glucose reabsorption, leading to increased urinary glucose excretion. The co-occurrence of T2DM and hypogonadism is known to be increasingly frequent. However, to date, no adverse events with the concomitant use of TRT and SGLT2is are reported. CASE DESCRIPTION: We report two cases of erythrocytosis during testosterone treatment and SGLT2i in patients with hypogonadism and T2DM. CONCLUSION: Considering that hypogonadism and T2DM are frequently associated, clinicians should carefully monitor the risk of occurrence of erythrocytosis when prescribing TRT and SGLT2i together.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Motta G, Zavattaro M, Romeo F, et al. Risk of Erythrocytosis During Concomitant Testosterone and SGLT2-Inhibitor Treatment: A Warning From Two Clinical Cases. J Clin Endocrinol Metab. 2019. PMID: 30395251. doi:10.1210/jc.2018-01702

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。